A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for SMD Rise PCL's Debt-to-EBITDA or its related term are showing as below:
BKK:SMD100-R'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.13 Med: 1.12 Max: 4.01
Current: 4.01
During the past 8 years, the highest Debt-to-EBITDA Ratio of SMD Rise PCL was 4.01. The lowest was 0.13. And the median was 1.12.
BKK:SMD100-R's Debt-to-EBITDA is ranked worse than 68.89% of 90
companies
in the Medical Distribution industry
Industry Median: 2.45
vs BKK:SMD100-R: 4.01
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
SMD Rise PCL Debt-to-EBITDA Related Terms
SMD Rise PCL Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for SMD Rise PCL's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:SMD100-R vs MCK, CAH, COR: Debt-to-EBITDA Comparison
For the Medical Distribution subindustry, SMD Rise PCL's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SMD Rise PCL Debt-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, SMD Rise PCL's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where SMD Rise PCL's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
SMD Rise PCL (BKK:SMD100-R) has a Debt-to-EBITDA of -7.21 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on SMD Rise PCL. Over the past decade, SMD Rise PCL's Debt-to-EBITDA has ranged from 0.13 to 4.01. According to the industry distribution chart, SMD Rise PCL ranks #62 out of 90 companies in the Medical Distribution industry, placing it in the top 68.9%.
Is SMD Rise PCL's Debt-to-EBITDA too high?
SMD Rise PCL's current Debt-to-EBITDA is -7.21. Over the past 10 years, this metric has ranged from a low of 0.13 to a high of 4.01. Based on the distribution chart, SMD Rise PCL ranks #62 out of 90 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, SMD Rise PCL has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does SMD Rise PCL's Debt-to-EBITDA compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, SMD Rise PCL ranks #62 out of 90 companies for Debt-to-EBITDA. This places SMD Rise PCL in the lower half of its industry. The industry median Debt-to-EBITDA is 2.45. Historically, SMD Rise PCL's own Debt-to-EBITDA has ranged from 0.13 to 4.01 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Distribution company?
The median Debt-to-EBITDA among Medical Distribution companies is 2.45, based on 90 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on SMD Rise PCL. For the Medical Distribution industry, the median Debt-to-EBITDA is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SMD Rise PCL's current Debt-to-EBITDA is -7.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SMD Rise PCL stock overvalued right now?
SMD Rise PCL (BKK:SMD100-R) has a current Debt-to-EBITDA of -7.21. The stock's GF Value™ is ฿24.10, compared to a current price of ฿5.85 — trading 75.7% below its estimated fair value. The current Debt-to-EBITDA is -7.21. SMD Rise PCL's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For SMD Rise PCL (BKK:SMD100-R), the current Debt-to-EBITDA is -7.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SMD Rise PCL (BKK:SMD100-R) Overvalued in 2026?
Based on GuruFocus' analysis, SMD Rise PCL stock appears to be undervalued.
The current stock price of ฿5.85 is trading 75.7% below its estimated GF Value™ of ฿24.10.
Key valuation signals for BKK:SMD100-R:
Debt-to-EBITDA: -7.21
GF Value™: ฿24.10 vs. price of ฿5.85 (75.7% below fair value)
No single metric tells the full story. See the BKK:SMD100-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Address222,222/1-2 Moo 1, Rattanathibet Road, West Inn Complex Building, 10th Floor, Bang Rak Yai Subdistrict, Bang Bua Thong District, Nonthaburi Province, Bangkok, THA, 11110
SMD Rise PCL, formerly Saintmed PCL is engaged in the import and distribution of medical devices and equipment, rental services for medical equipment, and providing services related to medical equipment. It operates in Thailand. The Group is engaged in three operating segments: Sale of medical devices and equipment, medical supplies, Services of medical equipment at sleep lab centers and repair services, and Revenue from rental of medical equipment at wellness centers and other services. The Group is managed and operates principally in Thailand.
60GF Score
Get the complete analysis for BKK:SMD100-R
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:SMD100-R has been successfully added to your 
